Successful Reduction of Preclinical Timelines via Optical Imaging

Highlighting successful case studies, this whitepaper demonstrates how optical imaging has been utilized to significantly reduce preclinical trial timelines. By employing bioluminescent and fluorescent technologies, researchers can capture more precise data early in the drug development process, thereby accelerating time to market while ensuring drug safety and efficacy.